218 related articles for article (PubMed ID: 29270668)
1. Cytosolic high-mobility group box protein 1 (HMGB1) and/or PD-1+ TILs in the tumor microenvironment may be contributing prognostic biomarkers for patients with locally advanced rectal cancer who have undergone neoadjuvant chemoradiotherapy.
Huang CY; Chiang SF; Ke TW; Chen TW; Lan YC; You YS; Shiau AC; Chen WT; Chao KSC
Cancer Immunol Immunother; 2018 Apr; 67(4):551-562. PubMed ID: 29270668
[TBL] [Abstract][Full Text] [Related]
2. Prognostic relevance of programmed cell death-ligand 1 expression and CD8+ TILs in rectal cancer patients before and after neoadjuvant chemoradiotherapy.
Chen TW; Huang KC; Chiang SF; Chen WT; Ke TW; Chao KSC
J Cancer Res Clin Oncol; 2019 Apr; 145(4):1043-1053. PubMed ID: 30874889
[TBL] [Abstract][Full Text] [Related]
3. Immunohistochemical detection of high-mobility group box 1 correlates with resistance of preoperative chemoradiotherapy for lower rectal cancer: a retrospective study.
Hongo K; Kazama S; Tsuno NH; Ishihara S; Sunami E; Kitayama J; Watanabe T
World J Surg Oncol; 2015 Jan; 13():7. PubMed ID: 25622595
[TBL] [Abstract][Full Text] [Related]
4. Upregulation of tumor PD-L1 by neoadjuvant chemoradiotherapy (neoCRT) confers improved survival in patients with lymph node metastasis of locally advanced rectal cancers.
Chiang SF; Huang CY; Ke TW; Chen TW; Lan YC; You YS; Chen WT; Chao KSC
Cancer Immunol Immunother; 2019 Feb; 68(2):283-296. PubMed ID: 30448924
[TBL] [Abstract][Full Text] [Related]
5. [Short-term outcome of programmed cell death protein1 (PD-1) antibody combined with total neoadjuvant chemoradiotherapy in the treatment of locally advanced middle-low rectal cancer with high risk factors].
Li YJ; Zhang L; Dong QS; Cai Y; Zhang YZ; Wang L; Yao YF; Zhang XY; Li ZW; Li YH; Sun YS; Wang WH; Wu AW
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Nov; 24(11):998-1007. PubMed ID: 34823301
[No Abstract] [Full Text] [Related]
6. CD8+ and FOXP3+ tumor-infiltrating T cells before and after chemoradiotherapy for rectal cancer.
Shinto E; Hase K; Hashiguchi Y; Sekizawa A; Ueno H; Shikina A; Kajiwara Y; Kobayashi H; Ishiguro M; Yamamoto J
Ann Surg Oncol; 2014 Jun; 21 Suppl 3():S414-21. PubMed ID: 24566864
[TBL] [Abstract][Full Text] [Related]
7. Implication of programmed cell death ligand 1 expression in tumor recurrence and prognosis in rectal cancer with neoadjuvant chemoradiotherapy.
Saigusa S; Toiyama Y; Tanaka K; Inoue Y; Mori K; Ide S; Imaoka H; Kawamura M; Mohri Y; Kusunoki M
Int J Clin Oncol; 2016 Oct; 21(5):946-952. PubMed ID: 26919982
[TBL] [Abstract][Full Text] [Related]
8. Significance of tumor-infiltrating lymphocytes before and after neoadjuvant therapy for rectal cancer.
Matsutani S; Shibutani M; Maeda K; Nagahara H; Fukuoka T; Nakao S; Hirakawa K; Ohira M
Cancer Sci; 2018 Apr; 109(4):966-979. PubMed ID: 29464828
[TBL] [Abstract][Full Text] [Related]
9. The local immune phenotype influences prognosis in patients with nodal-positive rectal cancer after neoadjuvant chemoradiation.
Schollbach J; Kircher S; Wiegering A; Anger F; Rosenwald A; Germer CT; Löb S
Int J Colorectal Dis; 2020 Feb; 35(2):365-370. PubMed ID: 31828368
[TBL] [Abstract][Full Text] [Related]
10. The therapeutic candidate for immune checkpoint inhibitors elucidated by the status of tumor-infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) expression in triple negative breast cancer (TNBC).
Tomioka N; Azuma M; Ikarashi M; Yamamoto M; Sato M; Watanabe KI; Yamashiro K; Takahashi M
Breast Cancer; 2018 Jan; 25(1):34-42. PubMed ID: 28488168
[TBL] [Abstract][Full Text] [Related]
11. Pattern of programmed cell death-ligand 1 expression and CD8-positive T-cell infiltration before and after chemoradiotherapy in rectal cancer.
Ogura A; Akiyoshi T; Yamamoto N; Kawachi H; Ishikawa Y; Mori S; Oba K; Nagino M; Fukunaga Y; Ueno M
Eur J Cancer; 2018 Mar; 91():11-20. PubMed ID: 29328976
[TBL] [Abstract][Full Text] [Related]
12. Intratumoral budding and automated CD8-positive T-cell density in pretreatment biopsies can predict response to neoadjuvant therapy in rectal adenocarcinoma.
Farchoukh L; Hartman DJ; Ma C; Celebrezze J; Medich D; Bahary N; Frank M; Pantanowitz L; Pai RK
Mod Pathol; 2021 Jan; 34(1):171-183. PubMed ID: 32661298
[TBL] [Abstract][Full Text] [Related]
13. Cytoplasmic expression of high mobility group B1 (HMGB1) is associated with tumor-infiltrating lymphocytes (TILs) in breast cancer.
Lee HJ; Kim A; Song IH; Park IA; Yu JH; Ahn JH; Gong G
Pathol Int; 2016 Apr; 66(4):202-9. PubMed ID: 26922571
[TBL] [Abstract][Full Text] [Related]
14. Co-expression of nuclear and cytoplasmic HMGB1 is inversely associated with infiltration of CD45RO+ T cells and prognosis in patients with stage IIIB colon cancer.
Peng RQ; Wu XJ; Ding Y; Li CY; Yu XJ; Zhang X; Pan ZZ; Wan DS; Zheng LM; Zeng YX; Zhang XS
BMC Cancer; 2010 Sep; 10():496. PubMed ID: 20846416
[TBL] [Abstract][Full Text] [Related]
15. High ratio of programmed cell death protein 1 (PD-1)(+)/CD8(+) tumor-infiltrating lymphocytes identifies a poor prognostic subset of extrahepatic bile duct cancer undergoing surgery plus adjuvant chemoradiotherapy.
Lim YJ; Koh J; Kim K; Chie EK; Kim B; Lee KB; Jang JY; Kim SW; Oh DY; Bang YJ; Ha SW
Radiother Oncol; 2015 Oct; 117(1):165-70. PubMed ID: 26235847
[TBL] [Abstract][Full Text] [Related]
16. Ki67 expression and localization of T cells after neoadjuvant therapies as reliable predictive markers in rectal cancer.
Imaizumi K; Suzuki T; Kojima M; Shimomura M; Sakuyama N; Tsukada Y; Sasaki T; Nishizawa Y; Taketomi A; Ito M; Nakatsura T
Cancer Sci; 2020 Jan; 111(1):23-35. PubMed ID: 31660687
[TBL] [Abstract][Full Text] [Related]
17. Natural killer-like signature observed post therapy in locally advanced rectal cancer is a determinant of pathological response and improved survival.
Alderdice M; Dunne PD; Cole AJ; O'Reilly PG; McArt DG; Bingham V; Fuchs MA; McQuaid S; Loughrey MB; Murray GI; Samuel LM; Lawler M; Wilson RH; Salto-Tellez M; Coyle VM
Mod Pathol; 2017 Sep; 30(9):1287-1298. PubMed ID: 28621318
[TBL] [Abstract][Full Text] [Related]
18. The Effects of Neoadjuvant Treatment on the Tumor Microenvironment in Rectal Cancer: Implications for Immune Activation and Therapy Response.
Chen CC; Wu ML; Huang KC; Huang IP; Chung YL
Clin Colorectal Cancer; 2020 Dec; 19(4):e164-e180. PubMed ID: 32387305
[TBL] [Abstract][Full Text] [Related]
19. Prognostic relevance of stromal CD26 expression in rectal cancer after chemoradiotherapy.
Saigusa S; Toiyama Y; Tanaka K; Inoue Y; Mori K; Ide S; Imaoka H; Kawamura M; Mohri Y; Kusunoki M
Int J Clin Oncol; 2016 Apr; 21(2):350-358. PubMed ID: 26370256
[TBL] [Abstract][Full Text] [Related]
20. Tumor-infiltrating lymphocytes, forkhead box P3, programmed death ligand-1, and cytotoxic T lymphocyte-associated antigen-4 expressions before and after neoadjuvant chemoradiation in rectal cancer.
Teng F; Meng X; Kong L; Mu D; Zhu H; Liu S; Zhang J; Yu J
Transl Res; 2015 Dec; 166(6):721-732.e1. PubMed ID: 26209749
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]